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D-Ala–D-Ala ligases in bacterial peptidoglycan biosynthesis
Vicki L Healy1, Ivan AD Lessard2, David I Roper3, James R Knox4 and
Christopher T Walsh1
Vancomycin binds to bacterial cell-wall intermediates to achieve
its antibiotic effect. Infections of vancomycin-resistant
enterococci are, however, becoming an increasing problem; the
bacteria are resistant because they synthesize different cell-wall
intermediates. The enzymes involved in cell-wall biosynthesis,
therefore, are potential targets for combating this resistance.
Recent biochemical and crystallographic results are providing
mechanistic and structural details about some of these targets.
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Introduction
Vancomycin belongs to the glycopeptide class of anti-
biotics, which are effective against gram-positive organ-
isms. In contrast, gram-negative bacteria are intrinsically
resistant to glycopeptides because of their impermeable
outer membrane. Glycopeptides are composed of a hepta-
peptide backbone that is substituted with five to seven
aromatic rings and different sugars. Vancomycin contains
two hexoses and five aromatic rings; chloroeremomycin has
an additional sugar molecule (Figure 1a,b). A second gly-
copeptide antibiotic approved for human use, teicoplanin,
contains three sugars and seven aromatic rings (Figure 1c).
In contrast to penicillin, which directly binds to and
inhibits the bifunctional transglycosylases/transpeptidases
involved in cell-wall biosynthesis, vancomycin binds to
the substrate of these enzymes, the D-alanyl–D-alanine
(D-Ala–D-Ala) terminus of the lipid-PP-disaccharide-pen-
tapeptide (Figure 2a). Binding of vancomycin to this
target is thought to sterically prevent the subsequent
action of both activities of the transglycosylase/transpepti-
dase: adding disaccharyl pentapeptide units to the
growing peptidoglycan (PG) strand and then cross-linking
peptides within and between PG strands on the external
face of the cytoplasmic membrane (Figure 2b). This
failure to form cross-links between peptidoglycan inter-
mediates lowers the rigidity of the cell wall and renders
these bacteria susceptible to osmotic lysis [1–5]. 
During the past decade, vancomycin has become the
front-line therapy for treating problematic infections
caused by methicillin-resistant Staphylococcus aureus
(MRSA), and by enterococci in patients after surgery. The
specter of vancomycin-resistant MRSA looms [6–9],
whereas vancomycin-resistant enterococci (VRE), which
cause high mortality rates, have become a distressingly
common reality in hospital settings [10,11]. Three VRE
phenotypes have been designated VanA, VanB and VanC
on the basis of the minimal inhibitory concentration
(MIC) in VRE and susceptibility to teicoplanin (Table 1)
[3,11]. The VanA and VanB phenotypes differ in that
VanA is resistant to teicoplanin, whereas VanB is not resis-
tant because the VanB resistance pathway is not activated
by teicoplanin (MIC ≤ 0.5 µg/ml) [3]. Both phenotypes are
the result of the incorporation into cell-wall intermediates
of a D-alanyl–D-lactate (D-Ala–D-Lac) depsipeptide syn-
thesized by the VanA or VanB ligase in place of the usual
D-Ala–D-Ala dipeptide. Vancomycin binds with a three
orders of magnitude lower affinity to D-Ala–D-Lac termini
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than to D-Ala–D-Ala termini (Figure 2a), and thus is less
able to sterically block the transpeptidation and trans-
glycosylation steps necessary for the formation of the pep-
tidoglycan cell wall [12]. 
In contrast to the VanA and VanB phenotypes, VanC resis-
tance in Enterococcus gallinarum and E. casseliflavus is chro-
mosomal, and has only been detected in a few clinical
isolates [11,13]. VanC resistance has a VanC D-alanyl–
D-serine (D-Ala–D-Ser) ligase in place of the D-Ala–D-Lac
ligases (VanA and VanB). The hydroxymethyl sidechain of
D-serine is thought to disrupt sterically the optimal geom-
etry for vancomycin binding to the usual D-Ala–D-Ala
termini, resulting in about a sixfold decrease in affinity for
vancomycin [14] and a corresponding eightfold increase in
the MIC for vancomycin (Table 1) [11]. VanD [15] and
VanE [16] clinical phenotypes have been described
recently, but are not yet completely characterized. 
D-Ala–D-X ligase superfamily
Homology analysis of the D-Ala–D-X (where X = alanine,
serine or lactate) superfamily of bacterial ligases revealed
five constituent families: two that are D-Ala–D-Ala ligases
physiologically, two that are D-Ala–D-Lac ligases and one
D-Ala–D-Ser ligase family (Figure 3) [17]. Many of the
residues shown by site-directed mutagenesis [18] and
structural studies [19] to be important for substrate binding
and catalysis by the Escherichia coli D-Ala-D-Ala ligase
(DdlB) are highly conserved among the entire Ddl super-
family. The D-Ala–D-Ala and D-Ala–D-Ser ligase (VanC)
families also have similar sequences for the projected
omega loop that closes over the active site of DdlB and the
loop contains Lys215 and Tyr216 (DdlB numbering),
which are important for catalysis (discussed further in the
next section) [17,18,20]. Of the two D-Ala–D-Lac ligase
families, the one represented by the Leuconostoc mesen-
teroides ligase (LmDdl2) has a comparable omega loop,
whereas the second, represented by the VanA and VanB
ligases and the DdlM from the glycopeptide antibiotic pro-
ducer Streptomyces toyocaensis, has a strikingly different
sequence of residues for the putative omega loop. The gain
of function to make the D-Ala–D-Lac depsipeptide is the
key molecular switch that reprograms the VanA and VanB
type VRE to produce a vancomycin-resistant cell wall.
E. coli DdlB as D-Ala–D-Ala ligase prototype
Until recently, the only available X-ray structure of a
D-Ala–D-X ligase superfamily member has been that of
the D-Ala–D-Ala ligase from E. coli (DdlB) with bound
ADP and a phosphorylated D-Ala–D-Ala phosphinate
transition-state inhibitor (Figure 4a,b) [19]. DdlB belongs
to the ATP-grasp superfamily of enzymes that have an
unusual nucleotide-binding fold [21–24]. All of these
ATP-grasp enzymes hydrolyze ATP to ADP and inor-
ganic phosphate and ligate one substrate with a carboxy-
late to a second substrate with a primary amine, secondary
amine, hydroxyl or thiol [25]. The catalytic mechanism of
these enzymes is also thought to include formation of an
R110 Chemistry & Biology 2000, Vol 7 No 5
Figure 1
Structure of glycopeptide antibiotics.
(a) Vancomycin. (b) Chloroeremomycin.
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activated acyl phosphate intermediate that is nucleophili-
cally attacked by the second substrate [26–29] (Figure 5). 
Structural alignment of DdlB with two other ATP-grasp
proteins, E. coli glutathione synthetase and biotin
carboxylase, revealed a similar binding site for ATP in a
cleft formed by two structural elements, each containing
two antiparallel β strands and a loop [22]. Despite only a
12% sequence identity between biotin carboxylase and
glutathione synthetase, 127 Cα atoms superimpose with a
root mean square deviation (rmsd) of only 1.64 Å [22].
Similarly, 101 Cα atoms of biotin carboxylase and DdlB
superimpose with a rmsd of 1.91 Å. In addition, most of
the amino acid residues that interact with ATP in DdlB
are conserved in all ATP-grasp proteins. For example,
Lys97 and Lys144 (DdlB numbering) are conserved in all
sequences except for substitution by arginine in car-
bamoyl phosphate synthetases [25]. This sequence con-
servation of all ATP-grasp proteins and the conserved
tertiary structure of three crystallized members support a
common evolutionary ancestor for these enzymes. 
On the basis of the crystal structure of DdlB, two loops close
over the catalytic cavity, as observed in other ATP-grasp
enzymes (Figure 4b) [19]. The first loop connects two
β strands and contains Glu148–Gly–Ser–Ser–Val–Gly. This
loop is part of a X–Gly–Ser–Ser–X–Gly motif, where posi-
tion X is variable, that is conserved in all D-Ala–D-X ligases
[17]. The second loop, called the omega loop, also connects
β strands and forms a short helix consisting of amino acids
206–220 [19].
The omega loop is believed to be flexible and exposed in
the uncomplexed enzyme [30]. The hydroxyl groups of
Ser150 and Ser151 of the first loop form three hydrogen
bonds to the omega loop and help hold it in place
(Figure 4b). Closing of the omega loop over the active site
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Figure 2
Mode of action of vancomycin. (a) Binding of
vancomycin to D-Ala–D-Ala and D-Ala–D-Lac
peptidoglycan termini. (b) Inhibition of
transglycosylation and transpeptidation steps
in cell-wall biosynthesis by vancomycin.
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Table 1
Resistance to glycopeptide antibiotics in the three classes of
vancomycin-resistant enterococci [3,11].
Vancomycin MIC Teicoplanin MIC 
Clinical phenotype (µg/ml) (µg/ml)
VanA >512 64
VanB >512 0.5
VanC 8 0.5
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of DdlB is thought to be required for most of the interac-
tions with ADP. The hydrogen-bond network of Glu15,
Ser150 and Tyr216 also orients Lys215 for stabilization of
γ-PO3 transfer to D-Ala in subsite 1 (D-Ala1; Figure 5b). A
solvent accessibility calculation shows that only 2% of the
surface area of the enzyme bound ADP and D-Ala–D-Ala
phosphinophosphate transition-state inhibitor is exposed,
so the loops are expected to be effective in preventing
hydrolysis of reactive intermediates (e.g. D-alanyl phos-
phate) by water [19]. 
Kinetic analysis of purified DdlB revealed a kcat value of
1870 min–1 at pH 7.8 for D-Ala–D-Ala synthesis but no
detectable D-Ala–D-Lac activity [18]. At pH 6.0, there is
very low D-Ala–D-Lac ligase activity that is less than 10%
of the dipeptide ligase activity and probably not physio-
logically significant, but this intrinsic activity could con-
tribute to the possible evolution of D-Ala–D-Lac ligases
from DdlB [31]. Electrostatic calculations [32] and the
slight decrease in D-Ala Km2 values as pH increases [31]
suggests that DdlB can utilize both the protonated and
deprotonated forms (NH3+ or NH2) of D-Ala at subsite 2
(D-Ala2) as substrates but may bind the deprotonated
form, which is more abundant at high pH, with higher
affinity. For D-Ala–D-Ala synthesis, DdlB binds Ala1 in
subsite 1 with high affinity (1 µM) but binds Ala2 in
subsite 2 with a 1000-fold weaker Km2 of 1.1 mM [18]. On
the basis of the in vivo concentration of 0.5 mM D-Ala in
exponentially growing E. coli, the rate of D-Ala–D-Ala for-
mation in vivo could be limited by the possible failure to
saturate subsite 2 of DdlB [33].
VanA/B family
In contrast to the D-Ala–D-Ala ligase families, the VanA
family synthesizes predominantly D-Ala–D-Lac by selec-
tively activating D-lactate while discriminating against
D-Ala2 (Table 2) [17,31]. Based on the pH profile of
D-Ala–D-Ala synthesis, VanA only utilizes the deproto-
nated (NH2) form of D-Ala2 as a substrate [17,31]. Thus,
one mechanism that VanA uses to minimize the amount of
D-Ala–D-Ala produced at physiological pH is to reject the
protonated (NH3+) form of D-Ala2 that is predominantly
present in solution (99.9% at pH 7.0). This result is in con-
trast to the electrostatic calculations [32] and weaker pH
dependence of dipeptide synthesis by DdlB [31] and
VanC2 (V.L.H., unpublished observations) that imply that
DdlB and VanC2 can utilize both the protonated and
deprotonated forms of amino acid substrates at subsite 2. 
Because the pH profiles for His244→Ala and Arg242→Ala
VanA mutants were less pH dependent and consisted of
Km2 values that were 2–3-fold lower than those of wild-
type VanA, His244 and Arg242 appeared partially respon-
sible for the rejection of the protonated (NH3+) form of
D-Ala at subsite 2 by VanA [17]. In the recently solved
X-ray structure of VanA from Enterococcus faecium, the
sidechain of His244 is 3.5 Å from the position in the
D-Ala–D-Ala phosphinate inhibitor corresponding to the
amino group D-Ala2 (Figure 6; D.I.R., T. Huyton,
A. Veguine and G. Dodson, unpublished observations).
His244 is therefore positioned in the active site such that
the protonated imidazole ring could help reject the proto-
nated form of D-Ala2. His244 is also involved in
D-Ala–D-Lac formation: mutation of His244→Ala resulted
in a 100-fold higher Km2 but only a twofold lower kcat [17].
Thus, the imidazole ring of His244 probably participates
in binding D-Lac. In contrast, Arg242 is exposed to
solvent, and thus, is less likely to play a role in repelling
D-Ala2 or binding D-Lac (D.I.R., T. Huyton, A. Veguine
and G. Dodson, unpublished observations).
Inclusion of the D-Ala–D-Lac ligase from the antibiotic
producer S. toyocaensis (DdlM) in the VanA ligase family
suggests that the VanA and VanB ligases in VRE may have
evolved from the resistance cassette in glycopeptide pro-
ducers (Figure 7) [34]. The presence of DdlM in addition
R112 Chemistry & Biology 2000, Vol 7 No 5
Figure 3
Phylogenetic tree of D-Ala–D-X ligase superfamily. From [17] with
permission. This alignment was obtained using the program Clustal W
[60]. Syn, Synechocystis sp.; Bsu, Bacillus subtilis; Enterococci,
Enterococcus sp. (Enterococcus faecalis); Streptococci, Streptococcus
sp. (Streptococcus pneumonia); Sco, Streptomyces coelicolor; Msm,
Mycobacterium smegmatis; Mtu, Mycobacterium tuberculosis; Bbu,
Borrelia burgdoferi; Hpy, Helicobacter pylori; Bap, Buchnera
aphidicola; Hin, Haemophilus influenzae; EcoB, Escherichia coli (ddlB);
Rpr, Rickettsia prowazekii; Aae, Aquifex aeolicus; Sto, Streptomyces
toyocaensis (ddlM ); Aor, Amycolatopsis orientalis (ddlN); BpoE,
Bacillus popilliae (vanE); OtuA2, Oerskovia turbata (vanA2); EfsA,
Enterococcus faecium (vanA); EfmB2, Enterococcus faecium (vanB2);
EfsB2, Enterococcus faecalis (vanB2); SboB2, Streptococcus bovis
(vanB2); EfmB, Enteroccus faecium (vanB); Ega, Enterococcus
gallinerum (vanC); Eca, Enterococcus casseliflavus (vanC2); Efl,
Enterococcus flavescens (vanC3); Lme, Leuconostoc mesenteroides;
Wco, Weassella confusa; Lpl, Lactobacillus plantarum; Lsa,
Lactobacillus salivarius; EcoA, E. coli (ddlA); Sty, Salmonella
typhimurium. Stars refer to alignments based on partial sequences. 
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to a D-Ala–D-Ala ligase in S. toyocaensis allows the bacteria
to switch from production of D-Ala–D-Ala to D-Ala–D-Lac
PG termini to generate self-immunity to the antibiotic it
produces. ddlM, with a high GC content of 65%, may have
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Figure 5
Formation of D-alanyl phosphate intermediate
and its capture by the nucleophilic substrate in
the reactions catalyzed by D-Ala–D-X ligases.
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Figure 4
Tertiary structure of the E. coli D-Ala–D-Ala
ligase DdlB [19]. (a) The overall folding of
DdIB showing the protected location of the
binding sites. ADP is shown in red; the
phosphinophosphate transition-state
inhibitor, in green. (b) The flexible omega
loop and Ser–Ser loop close over the DdlB
active site and orient residues for substrate
binding and catalysis. 
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been transferred via one or more bacterial intermediates
with a lower GC content to VRE, resulting in vanA and
vanB with GC contents (45% and 48%, respectively) that
are high for enterococcal genes. In addition the vanHAX
gene cluster in VRE has the same orientation and gene
alignment as that in S. toyocaensis [35,36]. Alternatively,
VanA and VanB may have evolved independently from
other D-Ala–D-X family members. 
Leuconostoc D-Ala–D-Lac ligase family
In addition to VRE, other gram-positive bacteria, such as
the Leuconostoc ligase family, are intrinsically resistant to
vancomycin because D-Ala–D-Lac is incorporated into
their cell wall [37,38]. The omega loop sequence for
LmDdl2 is similar to that of DdlB, except for the presence
of Phe261, which is required for D-Ala–D-Lac synthesis
and corresponds to the Tyr216→Phe (Y216F) DdlB
mutant with a gain of depsipeptide synthesis [20]. The
recent X-ray structure of LmDdl2 suggests that the
smaller size and greater hydrophobicity of the active site
than that of DdlB contribute to the 75-fold greater selec-
tivity for depsipeptide over dipeptide synthesis compared
to Y216F DdlB (Table 2; Figure 8) [20,39]. For example,
the replacement of the solvent-exposed His280 in DdlB
by the buried Met326 in van der Waals contact with the
phosphinate inhibitor in LmDdl2 would fill 55–60 Å3 of
the binding cavity, favoring binding of the smaller D-Lac
over D-Ala2 [39].
VanC family
In contrast to VanA and VanB classes of VRE, VanC-medi-
ated resistance is predominantly chromosomal and constitu-
tive [11,40]. VanC2 from E. casseliflavus is a D-Ala–Ser ligase
with no detectable D-Ala–D-Lac activity [41]. VanC2 has a
240-fold preference for D-serine over D-Ala2 in subsite 2
(Table 3) [41,42]. Modeling the structure of VanC2 on the
basis of the X-ray structure of the D-Ala-D-Ala ligase DdlB
[19] predicted that Arg322 and Phe250 could be responsible
for the greater affinity of D-Ser in the second binding site of
VanC2 [42]. This hypothesis was supported by mutating
these residues in VanC2 to the corresponding residues in
DdlB, resulting in a Phe250→Tyr/Arg322→Met VanC2
double mutant with reversed substrate specificity: the
mutant retained D-Ala–D-Ala ligase activity but had negligi-
ble D-Ala–D-Ser activity (Table 3) [42]. The guanidino
group of Arg322 probably hydrogen bonds to the hydroxyl
sidechain of D-Ser; however, the role of Phe250 in D-Ser
binding by VanC2 has not been determined.
The role of the putative VanC2 omega loop in substrate
specificity was further explored by generating VanA-based
chimeric proteins with portions of the omega loop of
VanC2 replacing that of VanA. These chimeras had a 5–6-
fold improvement in Km2 for D-Ala and D-Ser, possibly
resulting from a lessened discrimination against the zwit-
terionic form of substrate 2 [17]. This result suggests the
possibility that VanA could have evolved from a VanC2-
type framework. In addition, the chimeras failed to
produce detectable D-Ala–D-Lac, suggesting that the
VanA omega loop is necessary for utilization of D-Lac.
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Table 2
Gain of D-Ala–D-Lac ligase function [31,63]. 
D-Ala–D-lactate
Ligase D-Ala–D-Ala Ligase
E. coli DdlB <0.001 1
E. coli DdlB Y216F 0.04 >40-fold
L. mesenteroides 3 >3000-fold
S. toyocansis DdlM 4 >4000-fold
Enterococcal VanA 30 >30,000-fold
From [39].
Figure 6
Active site of the VanA D-Ala–D-Lac ligase
from E. faecium (D.I.R., T. Huyton, A. Veguine
and G. Dodson, unpublished observations).
The hydrogen-bond network involving four
water molecules shown in red and two
magenesium ions shown in yellow is thought
to help stabilize γ-phosphate transfer to the
phosphinate inhibitor or to D-Ala1 in the
normal reaction mechanism.
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Chemical mechanism of D-Ala–D-X ligases
The first step in the chemical mechanism of D-Ala–D-X
ligases is transfer of the γ-phosphate from ATP to D-Ala
forming the putative D-alanyl phosphate intermediate
(D-Ala1-P; Figure 5). In the second step, D-Ala1-P is cap-
tured by the nucleophilic substrate to generate the dipep-
tide or depsipeptide product. The reversible formation of
D-Ala1-P in the active sites of VanA, VanC2 and Ddl 
(Salmonella typhimurium Ddl or E. coli DdlB) is supported
by the D-Ala-dependent positional isotope [β,γ]-bridge to
nonbridge oxygen-18 scrambling of [γ-18O4]-ATP, molecu-
lar isotope exchange, and rapid quench studies [26] (and
V.L.H., unpublished observations). Although the common
intermediate D-Ala1-P is formed in each active site, the
VanA ligase differs from the others in not having the
expected Lys215 (DdlB numbering) cationic sidechain to
stabilize the PO3 group transferring from ATP to the car-
boxylate of D-Ala1, but instead has evolved an ordered array
of water molecules and metal ions to provide transition
state stabilization, as shown in Figure 6 (D.I.R., T. Huyton,
A. Veguine and G. Dodson, unpublished observations).
The X-ray structures for the DdlB [19], LmDdl2 [39] and
VanA ligases (D.I.R., T. Huyton, A. Veguine and
G. Dodson, unpublished observations), complexed with
the identical transition-state analog phosphinophosphate
(Figure 8a–c), reveal full conservation of the Glu15,
Ser150, Arg255 and Ser281 (DdlB numbering) that posi-
tion and orient the D-Ala1 and D-X substrates. The
D-Ala–D-Ala ligase (DdlB; Figure 8a) has Tyr216, whereas
the D-Ala-D-Lac ligase LmDdl2 (Figure 8b) has a change
to phenylalanine, disrupting a hydrogen-bond network.
This Tyr/Phe switch is one architectural element for
dipeptide to depsipeptide switching because the E. coli
DdlB F216Y mutant has a noticeable gain of D-Ala–D-Lac
synthesis (Table 2) and the LmDdl2 F261Y loses the dep-
sipeptide ligation activity [20]. VanA (Figure 8c) uses
His244 in this locale, oriented by Tyr315, suggesting a dif-
ferent mechanism from LmDdl2, which is a distinct
family of D-Ala–D-X ligases (Figure 3).
The second step in the reaction mechanism of these
ligases is the capture of D-Ala1-P by the nucleophilic
cosubstrate, D-Ala2, D-Ser or D-Lac, which must be depro-
tonated (from zwitterion to free amine form for D-Ala2 and
D-Ser; from alcohol to alkoxide for D-Lac) to engage in
peptide or depsipeptide bond formation. Despite the
X-ray structures, the identity of the catalytic base in these
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Figure 7
Comparison of vancomycin-resistance cassette in E. faecium to the
orientation of the corresponding genes in the antibiotic producer
S. toyocaensis [34]. 
1.0 2.0 3.0 4.0 5.0 6.0kb
vanR vanS vanH vanA vanX vanY vanZ
Enterococcus faecium (resistant) 
murX vanH st ddlM vanX st orf1
Streptomyces toyocaensis (producer)
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Comparison of environments of the phosphinophosphate analog in (a) the DdlB ligase (Protein Data Bank 2DLN), (b) the LmDdl2 ligase (Protein
Data Bank 1EHI), and (c) the VanA ligase [19,39] (D.I.R., T. Huyton, A. Veguine and G. Dodson, unpublished observations). Hydrogen bonds are
indicated by dashed lines. Hydrogen atoms are not drawn. Figure generated using MOLSCRIPT [61].
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steps is not resolved, and could, for example, be bound
water, Asp257 or even the phosphate group of D-Ala1-P for
DdlB [18]. For VanA, where only the minor, free base
form of D-Ala2 binds productively, a catalytic base may not
be provided by the protein when it makes D-Ala–D-Ala
[17]. When the protein makes D-Ala–D-Lac, His244 could
be involved, as indicated by the selective loss of two logs
of activity for D-Ala–D-Lac but not D-Ala–D-Ala formation
rates in the His244→Ala mutant [17] (D.I.R., T. Huyton,
A. Veguine and G Dodson, unpublished observations). 
In all the D-Ala–D-X ligases, it is likely that the loops
bearing Tyr216 (DdlB), Phe261 (LmDdl2) or His244
(VanA) open and close in each catalytic cycle to let prod-
ucts out and then when new substrates, D-Ala, D-Lac or
ATP, are bound they close down, orient substrates, and
sequester labile intermediates from hydrolysis and
prevent their release from the active site [19].
Companion enzymes 
The Ddl, VanA/B and VanC pathways all require two
additional enzymes to make PG: an alanine racemase for
generation of D-Ala as a D-Ala–D-X ligase substrate and an
enzyme for adding the D-Ala–D-X dipeptide/depsipeptide
product to a cytoplasmic PG precursor (Figure 9). D-Ala is
formed from conversion of L-Ala by alanine racemase.
E. coli has two genes encoding alanine racemases: alr
encodes a constitutive biosynthetic enzyme, while dadX
encodes a catabolic enzyme that is inducible by D/L-Ala.
After synthesis, D-Ala–D-X is added to an UDP-N-acetyl-
muramic acid (UDP-MurNAc) tripeptide moiety by the
enzyme MurF in an ATP-dependent mechanism [43].
Similar to the reaction catalyzed by the D-Ala–D-X ligases,
this reaction probably involves γ-phosphate transfer to the
UDP-MurNAc-tripeptide to form an acyl phosphate that
is then attacked by the D-Ala–D-X peptide/depsipeptide,
generating the UDP-MurNAc pentapeptide and inorganic
phosphate. The UDP-MurNAc pentapeptide is subse-
quently modified by addition of a lipid carrier and
N-acetylglucosamine to form the lipid-PP-disaccharide-
pentapeptide, which is translocated to the extracellular
side of the cytoplasm for incorporation into the cell wall.
For the VanA and VanB classes of vancomycin resistance,
the genes vanS, R, H and X are also required for resistance
[5,44]. VanH catalyzes the formation of D-Lac from pyru-
vate, which is then used by VanA or B to synthesize a
D-Ala–D-Lac depsipeptide [12]. VanX acts selectively as a
D-Ala–D-Ala dipeptidase, allowing only D-Ala–D-Lac to
accumulate and become incorporated into bacterial cell
wall intermediates in the presence of vancomycin [45,46].
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Table 3
Point mutants in VanC2 active site: reversion from D-Ala–D-Ser
to D-Ala–D-Ala ligase.
kcat/KM2 ratio
D-Ala2 Fold switch in
Mutants D-Ser specificity
VanC2 0.0042 1
F250Y 0.19 44
R322M 0.15 36
F250Y and R322M 26 6200
From [42].
Figure 9
Reactions catalyzed by alanine racemase and
MurF in cell-wall biosynthesis [43,62].
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An accessory enzyme not required for resistance, VanY,
which has D-carboxypeptidase activity, removes D-Ala
from peptidoglycan precursors ending in D-Ala–D-Ala [47].
In VanC-mediated resistance, a VanXYc protein has both
D-,D-carboxypeptidase and D-,D-dipeptidase activity [48].
The recently solved X-ray structure of VanX from
E. faecium with a bound D-Ala–D-Ala phosphinate inhibitor
reveals an active site with residues that serve a similar
function as DdlB residues Glu15, Ser218 and Arg255 that
are involved in electrostatic interactions with the ammo-
nium group of D-Ala1, the carboxylate of D-Ala2 and the
anionic transition state, respectively (Figure 10) [19,49,50].
The structure of VanX in the presence of a weakly bound
phosphonate inhibitor explains the poor binding of D-
Ala–D-Lac compared to D-Ala–D-Ala by VanX. The partial
negative charge of the phosphonate bridging oxygen is
repelled by the negatively charged Glu181 sidechain and a
mainchain carbonyl group of Tyr109; additionally, the
bridging oxygen could form an intraligand hydrogen bond
with the terminal amino group of the inhibitor, resulting in
the loss of a hydrogen bond between the amino group of
the inhibitor and the enzyme [49]. 
VanS and VanR form a two-component regulatory system
that senses vancomycin and regulates expression of the
vanH, A and X genes (Figure 11) [51]. VanS is a sensor
kinase that undergoes autophosphorylation on a con-
served histidine residue in its cytoplasmic domain and
then phosphoryl transfer to an aspartate residue on the
response regulator VanR, increasing the affinity of VanR
for the promoter region of the vanH, A, and X triad by
500-fold [52]. VanS autophosphorylation is induced by
vancomycin and teicoplanin in the VanA VRE phenotype
but only by vancomycin in the VanB phenotype. VanC
resistance is constitutive and thus does not seem to
require VanS or VanR. 
The VanC class of resistance also requires a membrane-
bound serine racemase that has been recently isolated
from E. gallinarum [53]. This pyridoxal 5′-phosphate-
dependent enzyme, VanT, racemizes L-Ser to the
D-enantiomer for use by the VanC ligase to generate
D-Ala–D-Ser. 
Strategies and progress in combating VRE
Given the rapid spread of VRE in hospitals and the high
mortality from such infections in immunocompromised
patients, there has been great interest in finding antibi-
otics that will kill VRE. One approach has been to use the
knowledge gained about the molecular logic of the cell
wall reprogramming from vancomycin-sensitive to van-
comycin-resistant bacteria to identify new targets. Clearly
VanA is one, along with the associated enzymes VanH
(the D-Lac dehydrogenase/pyruvate reductase) and VanX
(the D-Ala–D-Ala dipeptidase). The vanHAX structural
genes are controlled by a two-component sensor kinase-
response regulator pair, VanS and VanR, so all five of
these proteins are targets for inhibition of function and
reversal of VRE. The phosphinates that cocrystallize are
potent inhibitors of the D-Ala–D-X ligases in vitro [54] and
there are reports of inhibitors of two-component sensor/
response regulators [55], but to date no inhibitors of these
five proteins have been reported that can gain access to
the bacterial cytoplasm and have activity in vivo. A
second approach has been to screen natural product and
other compound libraries for efficacy against VRE. This
strategy has revealed that hydrophobic derivatives of van-
comycin family members, such as the N-(chloro-
biphenyl)-chloroeremomycin LY333328, is about two logs
more active than vancomycin against VRE [56]. Other
peptide-based drugs that have efficacy against VRE are
the quinuprustin/dalfoprustin combination Synercid [57]
and the lipodepsipeptide ramiplanin [58].
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Figure 10
Comparison of E. faecium and E. coli DdlB
active sites with bound phosphinate inhibitor
[19,49]. From [50].
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The D-Ala–D-X ligases remain an attractive target and as
ATP-grasp proteins they share common structural ele-
ments with members of the protein kinase family fold
[24]. There are large libraries of compounds that target
ATP sites of protein kinases [59] that have yet to be eval-
uated systematically against the D-Ala–D-X ligases.
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